The approval of three transformative spinal muscular atrophy therapies—SPINRAZA (Ionis/Biogen), EVRYSDI (Roche), and the groundbreaking gene therapy ZOLGENSMA (Novartis) has reshaped the spinal muscular atrophy treatment market. These breakthrough SMA medicines have significantly expanded SMA treatment options, offering meaningful clinical benefit across disease types, including spinal muscular atrophy type 1 treatments, spinal muscular atrophy type 2 treatments, and spinal muscular atrophy type 3 treatments.
Today, treating spinal muscular atrophy requires more than a single intervention. Modern spinal muscular atrophy treatment strategies emphasize a compre...
